Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes, constipation predominant, diarrhea predominant, and mixed; however, prior to 2017, only two ICD-10 codes existed: IBS with diarrhea and IBS without diarrhea. For the purposes of this analysis, we focus on the IBS without diarrhea population, which includes IBS-constipation (IBS-C). Limited treatment options are available for IBS, and only a few drugs have secured an FDA approval for IBS-C. Current treatment options include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), guanylate cyclase-C agonists (Allergan’s Linzess and Synergy Pharmaceuticals’ Trulance), and bicyclic fatty acids (Takeda’s Amitiza), all of which are only moderately effective in treating the disease.

QUESTIONS ANSWERED

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed IBS without diarrhea (including IBS-C)patients? What are the quarterly trends in prescribing among recently treated and new diagnosed IBS without diarrhea (including IBS-C) patients?
  • How have Linzess and Trulance been integrated into the treatment algorithm?
  • What proportion of IBS without diarrhea (including IBS-C) patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of IBS without diarrhea (including IBS-C) patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with IBS without diarrhea (including IBS-C)?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing brand share.

Table of contents

  • Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis - IBS Without Diarrhea (Including IBS Constipation) - (US)
    • Treatment Algorithms Claims Data Analysis IBS Without Diarrhea (Including IBS Constipation) January 2019

Author(s): Mohit Nasa, MBA

Mohit Nasa is a Lead Insights analyst on the Immune and Inflammatory team at Decision Resources Group and has authored content for indications like asthma and rheumatoid arthritis. He holds a Bachelor’s degree in Pharmacy and has earned his MBA in marketing and CRM from Amity Business School. Prior to joining DRG, Mohit worked as a Senior Business analyst at Novartis where he was responsible for end to end market assessment, reporting analytics and related projects for Novartis’s asthma brand Xolair. Mohit has also worked as Brand Manager at Ozone pharma and an Account Manager for IMS Health.


Related Reports

Irritable Bowel Syndrome | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis - IBS-Diarrhea (US)

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and...

View Details

Irritable Bowel Syndrome | Executive Insights | Executive Insights (US)

MARKET OVERVIEW The irritable bowel syndrome (IBS) market has experienced slow growth owing to a lack of disease understanding, low rate of patients seeking treatment, and few effective...

View Details

Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2018

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and ur...

View Details

Irritable Bowel Syndrome | Epidemiology | Middle East & Africa Data

DRG Epidemiology's coverage of irritable bowel syndrome comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of irritable bow...

View Details